# Adrecizumab in Cardiogenic Shock

Study · id `cardio:ct-nct03989531` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03989531](<https://clinicaltrials.gov/study/NCT03989531>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03989531

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT03989531. Randomized; quadruple masking; primary purpose treatment. Start 2019-04-04 (actual); primary completion 2021-04-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT03989531, source copy `cardio:ctgov-nct03989531-2021-10-08`, retrieved 2026-10-31)
- Started: 2019-04-04 (actual) (ClinicalTrials.gov record NCT03989531, source copy `cardio:ctgov-nct03989531-2021-10-08`, retrieved 2026-10-31)
- Primary completion: 2021-04-26 (actual) (ClinicalTrials.gov record NCT03989531, source copy `cardio:ctgov-nct03989531-2021-10-08`, retrieved 2026-10-31)
- Completion: 2021-04-26 (actual) (ClinicalTrials.gov record NCT03989531, source copy `cardio:ctgov-nct03989531-2021-10-08`, retrieved 2026-10-31)
- Countries: Germany (ClinicalTrials.gov record NCT03989531, source copy `cardio:ctgov-nct03989531-2021-10-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03989531-2021-10-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Adrecizumab in Cardiogenic Shock
- Acronym: ACCOST-HH
- Condition: Cardiogenic Shock
- Condition: Endothelial Dysfunction
- Intervention (Biological): Adrecizumab
- Intervention (Drug): Placebo
- Lead sponsor: Dr. med. Mahir Karakas
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial (`cardio:pubmed-34895483`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 259e166a4a95af0c53674665ee7f5d6dee9acffdb93146164156ba52d9c01653
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
